Leadinno

Leadinno operates across two related but distinct medical-device areas: neuromodulation for pain and neurological conditions, and minimally invasive spinal surgery. Its InnoPulse-SCS system is described as a wireless-powered implantable spinal cord stimulation device; its stated design approach aims to reduce reliance on an implanted pulse generator and battery. The company is also developing a wireless peripheral nerve stimulation implant and sells a complementary range of spine endoscopy systems, including InnoSpine and SpineInno-TOP and -UBE products. The available similar-company entries repeat Leadinno itself rather than identifying genuine peers, so named competitors cannot be reliably assessed. Its competitive position therefore depends on execution across product development, evidence generation, regulatory progress, and adoption by clinicians. The combination of implantable stimulation and surgical devices also means it serves overlapping pain-care pathways, but there is not enough information to determine whether those products are integrated commercially or clinically.

Leadinno’s financing history indicates a progression from a CNY 29 million seed round in July 2021 to two CNY 100 million Series A rounds in September 2022 and October 2023. It then raised CNY 200 million in October 2025 and another CNY 200 million in August 2026. The five listed rounds total CNY 629 million, or approximately $90.3 million. The 2025 and 2026 financings are notable inflection points in scale and include institutional and regional investors; the latest round’s classification is described inconsistently, with a financing headline using B+ and B++ labels while the round entry is labeled Series B. Product development has expanded from wireless-powered spinal cord stimulation toward peripheral nerve stimulation, alongside a portfolio of minimally invasive spinal endoscopy systems. Patent publications from 2022 cover implantable neurostimulation and wireless energy transfer, indicating technical development in these areas but not, by themselves, proving product readiness or commercial adoption. Its employee-size band is listed as 10,001+, an unusually large figure for a company of this profile and one that merits verification before drawing conclusions about workforce scale.